
Neurocrine Biosciences (NBIX) Stock Forecast & Price Target
Neurocrine Biosciences (NBIX) Analyst Ratings
Bulls say
Neurocrine Biosciences is in a strong financial position, with increasing revenues and a growing pipeline of promising drug candidates. Their focus on neurological, psychiatric, endocrine, and immunological disorders presents numerous potential opportunities for growth. Additionally, the company's expansion into rare diseases and endocrinology through acquisitions and the potential success of Crenessity could lead to increased revenue and profitability.
Bears say
Neurocrine Biosciences is a biopharmaceutical company specializing in treatments for neurological, endocrine, and psychiatric disorders. While the company has a diverse pipeline of drug candidates and currently has FDA-approved treatments for some of these conditions, there are concerns about the sustainability of these treatments and the potential for new competition in the market. Additionally, there is a risk of setbacks in R&D, regulatory issues, or commercial challenges that could impact the company's financial results. Overall, there are potential barriers to adoption of Neurocrine's treatments, and there is uncertainty about the company's future outlook.
This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Neurocrine Biosciences (NBIX) Analyst Forecast & Price Prediction
Start investing in Neurocrine Biosciences (NBIX)
Order type
Buy in
Order amount
Est. shares
0 shares